JP2025503513A5 - - Google Patents
Info
- Publication number
- JP2025503513A5 JP2025503513A5 JP2024538668A JP2024538668A JP2025503513A5 JP 2025503513 A5 JP2025503513 A5 JP 2025503513A5 JP 2024538668 A JP2024538668 A JP 2024538668A JP 2024538668 A JP2024538668 A JP 2024538668A JP 2025503513 A5 JP2025503513 A5 JP 2025503513A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- sequence
- sequence shown
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111639610 | 2021-12-29 | ||
| CN202111639610.2 | 2021-12-29 | ||
| PCT/CN2022/142626 WO2023125611A1 (zh) | 2021-12-29 | 2022-12-28 | 靶向cd3的抗体及多特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503513A JP2025503513A (ja) | 2025-02-04 |
| JP2025503513A5 true JP2025503513A5 (enExample) | 2026-02-17 |
Family
ID=86997950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538668A Pending JP2025503513A (ja) | 2021-12-29 | 2022-12-28 | Ｃｄ３を標的にする抗体、多特異性抗体、およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250059278A1 (enExample) |
| EP (1) | EP4458861A1 (enExample) |
| JP (1) | JP2025503513A (enExample) |
| CN (1) | CN118591561A (enExample) |
| WO (1) | WO2023125611A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20260103519A1 (en) * | 2024-10-11 | 2026-04-16 | Ibio, Inc. | Bispecific, modulatable antibody or antigen binding fragments thereof |
| CN122255272A (zh) * | 2024-12-19 | 2026-06-23 | 上海橙帆医药有限公司 | 具有t细胞激活功能的抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| US10730954B2 (en) * | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| CN111269315B (zh) * | 2019-06-19 | 2022-04-08 | 北京智仁美博生物科技有限公司 | 针对bcma的单克隆抗体 |
| CN111171155B (zh) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
-
2022
- 2022-12-28 WO PCT/CN2022/142626 patent/WO2023125611A1/zh not_active Ceased
- 2022-12-28 CN CN202280085681.9A patent/CN118591561A/zh active Pending
- 2022-12-28 EP EP22914863.0A patent/EP4458861A1/en active Pending
- 2022-12-28 US US18/723,721 patent/US20250059278A1/en active Pending
- 2022-12-28 JP JP2024538668A patent/JP2025503513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058345A5 (enExample) | ||
| Jain et al. | Engineering antibodies for clinical applications | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| JP2022515318A5 (enExample) | ||
| JP2025078629A (ja) | 多重特異性抗体 | |
| JP7611931B2 (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2020501531A5 (enExample) | ||
| JP2021534802A5 (enExample) | ||
| CA3196809A1 (en) | Combination treatment | |
| WO2022136647A1 (en) | Human ccr8 binders | |
| JP2018532766A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| WO2022143801A1 (en) | Multispecific antigen binding proteins | |
| CA3074524A1 (en) | Novel anti-cd19 antibodies | |
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Accardi et al. | Antibodies in single-chain format against tumour-associated antigens: present and future applications | |
| JP2025504496A5 (enExample) | ||
| WO2021041300A2 (en) | Bispecific antibodies and uses thereof | |
| JP2025542154A (ja) | 抗体及びその用途 | |
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 |